Hi Terry,

After doing the analysis, I observeobserved that there are existence ofexist similar Reportingreporting rules satisfyingto satisfy our present scenario with the Enzalutamide reporting to PI in US, in the absence of US License to the reporting destinations “ {CT} PFE Clinical Teams” and “{PCO} USA-USCS”USA-USCS.”

Below are the RR’s configured for the destinations “ {CT} PFE Clinical Teams” and “{PCO} USA-USCS”USA-USCS.”
· 7d {PCO} USCS - Inv (Dom) - LP-Janssen

· 15d {PCO} USCS - Inv (Dom) - LP-Janssen

· 7d {CT} PFE CT- Inv (Dom) - LP-Janssen

· 15d {CT} PFE CT - Inv (Dom) - LP-Janssen


These Reporting rules are associated with the below Jassen Product families (which are included from the advanceadvanced condition):
· ACC-001-FAM

· BAPINEUZUMAB-FAM

· PF-05236812-FAM

· PF-05236807-FAM


These products also do not have US license, but the cases are reported to the above destinations, with the help of a “World” license configured to the products, and RR’s are configured such that to include only cases having COI= USA and Causality as “Related” and Listednessare listed as “Unlisted” (Included from the Advance Condition RR: SAF01-USCS Inv Dom Reporting Janssen 2013-09-10).

Please find, attached, a miniCBD for more understanding and also let me know if you have any further questions.